Cite
HARVARD Citation
De Vita, S. et al. (n.d.). THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study. Annals of the rheumatic diseases. pp. 338-339. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
De Vita, S. et al. (n.d.). THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study. Annals of the rheumatic diseases. pp. 338-339. [Online].